Impact of Probiotic Preparation VSL#3 on Infants Colics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infantile colic is one of the most commonly reported medical problems within the first three months of life causing appreciable distress for both parents and pediatricians.

It appears that multiple independent origins might be involved: amongst them infant's difficult temperament, inadequate mother-infant communication or maternal anxiety, transient lactase deficiency, exposure to cow's milk, abnormal gastrointestinal function, maternal smoking during pregnancy or after delivery. Consequently, various treatment approaches have been tried to alleviate this condition.

Recent studies have suggested that changes of intestinal microflora of a newborn may play an important role in pathogenesis of infantile colic. Therefore, dietary supplementation with probiotics has been proposed for the improvement of this condition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of a Partially Hydrolyzed Formula, Containing Lactobacillus Reuteri, for Infant Colic

NCT02813772

Infant Colics

UNKNOWN NA

Effect of Milk Formula Supplemented With L. Reuteri on Crying Time in Colicky Infants Less Than 3 Months Old

NCT02430831

Infantile Colic

UNKNOWN PHASE4

Effects of Vivatlac Baby on Crying Behavior of Colicky Babies

NCT04487834

Infantile Colic

COMPLETED PHASE2

Effects of Multilac Baby on Fecal Calprotectin Levels of Colicky Babies

NCT04666324

Infantile Colic

UNKNOWN NA

Infantile Colic: Study of the Efficacy of Lactobacillus GG (ATCC 53103) Plus Chamomile in Breastfeeding Infants

NCT03477669

Infantile Colic

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim of the study is to evaluate the improvement of colics symptoms by the oral administration of VSL#3 and the difference in the daily average crying time (measured with parental diary) between end of treatment and baseline.

In this study, 62 infants will be enrolled and will receive 10 drops per day of VSL#3 or Placebo according to randomization list. The study product will be supplied as a box containing the oil bottle and a powder stick. The product should be stored refrigerated. On the first day of supplementation, the mother will open the sachet, pour the contents into the bottle and shake vigorously. A dropper is provided to count the drops. The suspension must be shaken vigorously before every use. Compliance will be monitored by filling out a diary.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infant Colics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VSL#3 drops

31 infants will receive 10 drops active product that should be taken daily (preferably in the morning before feeding) for 21 days.

Group Type ACTIVE_COMPARATOR

VSL#3 drops

Intervention Type DIETARY_SUPPLEMENT

VSL#3 drops placebo

31 infants will receive 10 drops of placebo product that should be taken daily (preferably in the morning before feeding) for 21 days.

Group Type PLACEBO_COMPARATOR

VSL#3 drops placebo

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VSL#3 drops

Intervention Type DIETARY_SUPPLEMENT

VSL#3 drops placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants aged between 30 and 90 days
* Breast fed exclusively during length of trial
* Diagnosis of infantile colic according to Wessel's criteria i.e paroxysmal fussing in infancy for more than three hours per day, at least three days per week but not treated previously for colics.
* Debut of colic symptoms 6+/-1 days before randomization
* Written informed consent from one or both parents
* Stated availability and reliability throughout the study period.

Exclusion Criteria

* Major chronic disease
* Gastrointestinal disease
* Administration of antibiotics the week before randomization
* Administration of probiotics two weeks before randomization
* Infants with GI malformation, cystic fibrosis, other genetic diseases
* Participation in other clinical trials.

Minimum Eligible Age

30 Days

Maximum Eligible Age

90 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No